News | August 27, 2003

Genetix launches the aliQuot

Genetix Group plc (LSE: GTX), the genomics and proteomics technology group, today announces the launch of an automated solution for low volume dispensing, the aliQuot, at the Drug Discovery Technology conference in Boston, USA.

The aliQuot utilizes Genetix's skills developed on the QFill2, and takes them a stage further. A proprietary fast pressure-timing dispense mechanism allows the aliQuot to fill a 1536-well plate with 1µl in under 30 seconds with a well-to-well CV of approx. 5% - a level of accuracy unsurpassed by any other instrument in its price bracket.

This versatility, fast dispense action, backfilling facility and optional microplate stacker, the aliQuot is the complete solution to your low-volume dispensing needs. The aliQuot is the perfect choice for automated dispensing of reagents, chemicals, cells, beads, reaction mixes and medium in the 1-350 µl range.

With the aliQuot, all your low-volume dispensing needs are met in one instrument. The aliQuot allows you to precisely dispense into 1536-, 384- and 96-well microplates including Genetix low profile, standard height and deep-well microplates. A range of interchangeable reagent reservoirs, ranging from 60 ml to 2 litres in volume, is available to suit the requirements of each individual dispensing run and reagent. Furthermore, the aliQuot is compatible with aqueous and DMSO-based solutions and is programmable for liquids of different viscosities. This versatile system is small enough to fit into a laminar flow cabinet for sterile dispensing application, and can be controlled remotely using an RS232 port.

To conserve precious reagents that remain in the manifold and tubing at the end of a run a backfilling function flushes unused reagent back into the reservoir bottle for future use.

The major markets for this product will be: Drug Discovery (cell-based assays, enzyme assays), Forensics (PCR, ELISA, enzyme assays), Genetic Screening (well plate arrays – DNA, protein, ELISA, PCR-ELISA, SNPs), Genomics research (high throughput PCR, sequencing reactions, SNPs) & HTS (compound library screening, cell-based assays).

Future developments are likely to include the simultaneous dispensing of up to eight reagents.

Julian Burke PhD, Chief Scientific Officer of Genetix, commented:

"The AliQuot will have a major impact in the area of low volume dispensing. This machine responds directly to the needs of our customers. We are highly encouraged by the early interest shown by pharmaceutical companies, even before its official launch."